Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Eine Studie mit einem neuen Medikament, Nivolumab, in Kombination mit Chemotherapeutika zur Behandlung einer Krebsart namens Nasopharynxkarzinom (NPC)

13. Oktober 2026 aktualisiert von: National Cancer Institute (NCI)

Eine Phase-2-Studie mit Chemoimmuntherapie mit Gemcitabin, Cisplatin und Nivolumab bei neu diagnostiziertem Nasopharynxkarzinom (NPC)

This phase II trial tests effects of nivolumab in combination with chemotherapy drugs prior to radiation therapy patients with nasopharyngeal carcinoma (NPC). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as gemcitabine and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. Researchers want to find out what effects, good and/or bad, adding nivolumab to chemotherapy has on patients with newly diagnosed NPC. In addition, they want to find out if children with NPC may be treated with less radiation therapy and whether this decreases the side effects of therapy.

Studienübersicht

Detaillierte Beschreibung

PRIMARY OBJECTIVE:

I. To evaluate safety of combining chemotherapy (cisplatin and gemcitabine) with an anti-PD1 immune checkpoint inhibitor (nivolumab) in children, adolescents and young adults with nasopharyngeal carcinoma (NPC) by determining the rate of Common Terminology Criteria for Adverse Events (CTCAE) grade 3 or higher immune related adverse events (irAEs).

SECONDARY OBJECTIVES:

I. To estimate the 2-year event-free survival (EFS) of children, adolescents and young adults with NPC who are treated with induction chemoimmunotherapy (CIT), followed by consolidation chemoradioimmunotherapy (CRIT, cisplatin, nivolumab and response-adjusted, dose de-escalated radiation therapy), and nivolumab maintenance therapy.

II. To evaluate the objective response rate (ORR) including complete responders and partial responders (complete response [CR] + partial response [PR]) of neoadjuvant CIT.

III. To evaluate feasibility of combining chemotherapy (cisplatin and gemcitabine) with an anti-PD1 immune checkpoint inhibitor (nivolumab) in children, adolescents and young adults with nasopharyngeal carcinoma (NPC).

IV. To evaluate the cumulative incidence of local and distant relapse.

EXPLORATORY OBJECTIVES:

I. To estimate 5-year EFS and overall survival (OS) of children with NPC who are treated with induction CIT followed by consolidation CRIT, and nivolumab maintenance therapy.

II. To compare response assessed by fludeoxyglucose F18 (FDG) positron emission tomography (PET) versus magnetic resonance imaging (MRI).

III. To determine treatment outcomes for patients treated with radiation per protocol versus (vs) deviation.

IV. To evaluate outcomes comparing patients receiving intensity modulated radiation therapy (IMRT) to proton therapy.

V. To objectively measure both acute and long-term toxicity including immune related adverse events and radiation late effects.

VI. To evaluate swallowing dysfunction using patient reported outcome (PRO) measures for children and adults throughout the protocol for up to 5 years.

VII. To evaluate quality of life (QOL) using Patient-Reported Outcomes Measurement Information System (PROMIS) multidimensional questionnaire throughout the protocol for up to 5 years.

VIII. To correlate the lymphocyte to monocyte ratio on complete blood counts (CBCs) with treatment response and outcomes.

IX. To collect and bank specimens (including tumor, blood and stool) for future research studies.

OUTLINE:

INDUCTION THERAPY: Patients receive nivolumab intravenously (IV) over 30 minutes on day 1 of each cycle, gemcitabine IV over 30 minutes on days 1 and 8 of each cycle, and cisplatin IV over 3-6 hours on day 1 of each cycle. Treatment repeats every 21 days for 3 cycles in the absence of disease progression or unacceptable toxicity.

CONSOLIDATION THERAPY: Patients receive nivolumab IV over 30 minutes on day 1 of each cycle and cisplatin IV over 3-6 hours on day 1 of cycles 1-2. Treatment repeats every 21 days for 3 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive concurrent radiation therapy on trial.

MAINTENANCE THERAPY: Patients receive nivolumab IV over 30 minutes on day 1 of each cycle. Treatment repeats every 28 days for 6 cycles in the absence of disease progression or unacceptable toxicity.

Patients also undergo echocardiography (ECHO) or multigated acquisition scan (MUGA) during screening and as clinically indicated on trial. Patients undergo MRI, FDG PET, and computed tomography (CT) throughout the trial and chest x-ray during follow-up. Patients also undergo dental x-ray imaging on the trial. Patients may optionally undergo tissue biopsy, blood and stool sample collection during screening and on trial.

After completion of study treatment, patients are followed up every 3 months for 12 months, every 6 months until 24 months off therapy, and then yearly until 5 years off therapy.

Studientyp

Interventionell

Einschreibung (Geschätzt)

50

Phase

  • Phase 2

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

    • New South Wales
      • Hunter Regional Mail Centre, New South Wales, Australien, 2310
        • Rekrutierung
        • John Hunter Children's Hospital
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: (02) 4985 5180
        • Hauptermittler:
          • Kristy McCarthy
    • Alberta
      • Calgary, Alberta, Kanada, T3B 6A8
        • Rekrutierung
        • Alberta Children's Hospital
        • Kontakt:
        • Hauptermittler:
          • Victor A. Lewis
      • Edmonton, Alberta, Kanada, T6G 2B7
        • Rekrutierung
        • University of Alberta Hospital
        • Kontakt:
        • Hauptermittler:
          • Sarah J. McKillop
    • Ontario
      • Toronto, Ontario, Kanada, M5G 1X8
        • Rekrutierung
        • Hospital for Sick Children
        • Kontakt:
        • Hauptermittler:
          • Avram E. Denburg
    • Quebec
      • Montreal, Quebec, Kanada, H3H 1P3
        • Rekrutierung
        • The Montreal Children's Hospital of the MUHC
        • Kontakt:
        • Hauptermittler:
          • Stephanie Mourad
      • Montreal, Quebec, Kanada, H3T 1C5
        • Rekrutierung
        • Centre Hospitalier Universitaire Sainte-Justine
        • Hauptermittler:
          • Monia Marzouki
        • Kontakt:
      • Sherbrooke, Quebec, Kanada, J1H 5N4
        • Rekrutierung
        • Centre Hospitalier Universitaire de Sherbrooke-Fleurimont
        • Kontakt:
        • Hauptermittler:
          • Stephanie Vairy
      • Christchurch, Neuseeland, 8011
        • Rekrutierung
        • Christchurch Hospital
        • Hauptermittler:
          • Tristan Pettit
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 03 364 0640
    • Auckland
      • Grafton, Auckland, Neuseeland, 1145
        • Rekrutierung
        • Starship Children's Hospital
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 0800 728 436
        • Hauptermittler:
          • Leander D. Timothy
      • San Juan, Puerto Rico, 00926
        • Rekrutierung
        • University Pediatric Hospital
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 787-474-0333
        • Hauptermittler:
          • Maria E. Echevarria
    • Alabama
      • Birmingham, Alabama, Vereinigte Staaten, 35233
        • Rekrutierung
        • Children's Hospital of Alabama
        • Kontakt:
        • Hauptermittler:
          • Jamie M. Aye
    • Arizona
      • Phoenix, Arizona, Vereinigte Staaten, 85016
        • Rekrutierung
        • Phoenix Childrens Hospital
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 602-546-0920
        • Hauptermittler:
          • Alok K. Kothari
    • Arkansas
      • Little Rock, Arkansas, Vereinigte Staaten, 72202-3591
        • Rekrutierung
        • Arkansas Children's Hospital
        • Hauptermittler:
          • Michael W. Bishop
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 501-364-7373
    • California
      • Downey, California, Vereinigte Staaten, 90242
        • Rekrutierung
        • Kaiser Permanente Downey Medical Center
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 626-564-3455
        • Hauptermittler:
          • Robert M. Cooper
      • Loma Linda, California, Vereinigte Staaten, 92354
        • Rekrutierung
        • Loma Linda University Medical Center
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 909-558-4050
        • Hauptermittler:
          • Albert Kheradpour
      • Los Angeles, California, Vereinigte Staaten, 90027
        • Rekrutierung
        • Children's Hospital Los Angeles
        • Hauptermittler:
          • Rachana Shah
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 323-361-4110
      • Madera, California, Vereinigte Staaten, 93636
        • Rekrutierung
        • Valley Children's Hospital
        • Kontakt:
        • Hauptermittler:
          • Ruetima Titapiwatanakun
      • Oakland, California, Vereinigte Staaten, 94611
        • Rekrutierung
        • Kaiser Permanente-Oakland
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 877-642-4691
          • E-Mail: Kpoct@kp.org
        • Hauptermittler:
          • Aarati V. Rao
      • Oakland, California, Vereinigte Staaten, 94609
        • Rekrutierung
        • UCSF Benioff Children's Hospital Oakland
        • Hauptermittler:
          • Jennifer G. Michlitsch
        • Kontakt:
      • San Diego, California, Vereinigte Staaten, 92123
        • Rekrutierung
        • Rady Children's Hospital - San Diego
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 858-966-5934
        • Hauptermittler:
          • William D. Roberts
      • San Francisco, California, Vereinigte Staaten, 94158
        • Rekrutierung
        • UCSF Medical Center-Mission Bay
        • Kontakt:
        • Hauptermittler:
          • Arun A. Rangaswami
    • Colorado
      • Aurora, Colorado, Vereinigte Staaten, 80045
        • Rekrutierung
        • Children's Hospital Colorado
        • Hauptermittler:
          • Navin R. Pinto
        • Kontakt:
    • Connecticut
      • Hartford, Connecticut, Vereinigte Staaten, 06106
        • Rekrutierung
        • Connecticut Children's Medical Center
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 860-545-9981
        • Hauptermittler:
          • Michael S. Isakoff
    • Delaware
      • Wilmington, Delaware, Vereinigte Staaten, 19803
        • Rekrutierung
        • Alfred I duPont Hospital for Children
        • Kontakt:
        • Hauptermittler:
          • Sridhi Patel
    • District of Columbia
      • Washington D.C., District of Columbia, Vereinigte Staaten, 20010
        • Rekrutierung
        • Children's National Medical Center
        • Hauptermittler:
          • Jeffrey S. Dome
        • Kontakt:
    • Florida
      • Gainesville, Florida, Vereinigte Staaten, 32610
        • Rekrutierung
        • UF Health Cancer Institute - Gainesville
        • Kontakt:
        • Hauptermittler:
          • Brian Stover
      • Jacksonville, Florida, Vereinigte Staaten, 32207
        • Rekrutierung
        • Nemours Children's Clinic-Jacksonville
        • Kontakt:
        • Hauptermittler:
          • Sridhi Patel
      • Miami, Florida, Vereinigte Staaten, 33155
        • Rekrutierung
        • Nicklaus Children's Hospital
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 888-624-2778
        • Hauptermittler:
          • Ziad A. Khatib
      • Orlando, Florida, Vereinigte Staaten, 32806
        • Rekrutierung
        • Arnold Palmer Hospital for Children
        • Kontakt:
        • Hauptermittler:
          • Zhongbo Hu
      • Orlando, Florida, Vereinigte Staaten, 32827
        • Rekrutierung
        • Nemours Children's Hospital
        • Kontakt:
        • Hauptermittler:
          • Sridhi Patel
      • Pensacola, Florida, Vereinigte Staaten, 32504
      • Tampa, Florida, Vereinigte Staaten, 33607
        • Rekrutierung
        • Saint Joseph's Hospital/Children's Hospital-Tampa
        • Kontakt:
        • Hauptermittler:
          • Don E. Eslin
    • Georgia
      • Atlanta, Georgia, Vereinigte Staaten, 30329
        • Rekrutierung
        • Children's Healthcare of Atlanta - Arthur M Blank Hospital
        • Hauptermittler:
          • Sarah G. Mitchell
        • Kontakt:
    • Illinois
      • Chicago, Illinois, Vereinigte Staaten, 60611
        • Rekrutierung
        • Lurie Children's Hospital-Chicago
        • Hauptermittler:
          • Amy L. Walz
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 773-880-4562
      • Chicago, Illinois, Vereinigte Staaten, 60637
        • Suspendiert
        • University of Chicago Comprehensive Cancer Center
    • Indiana
      • Indianapolis, Indiana, Vereinigte Staaten, 46202
        • Rekrutierung
        • Riley Hospital for Children
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 800-248-1199
        • Hauptermittler:
          • Marissa Just
    • Kentucky
      • Lexington, Kentucky, Vereinigte Staaten, 40536
        • Noch keine Rekrutierung
        • University of Kentucky/Markey Cancer Center
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 859-257-3379
        • Hauptermittler:
          • James T. Badgett
    • Louisiana
      • New Orleans, Louisiana, Vereinigte Staaten, 70118
        • Rekrutierung
        • Children's Hospital New Orleans
        • Hauptermittler:
          • Maria C. Velez-Yanguas
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 504-894-5377
    • Maine
      • Scarborough, Maine, Vereinigte Staaten, 04074
        • Rekrutierung
        • Maine Children's Cancer Program
        • Hauptermittler:
          • Aaron R. Weiss
        • Kontakt:
    • Maryland
      • Baltimore, Maryland, Vereinigte Staaten, 21287
        • Rekrutierung
        • Johns Hopkins University/Sidney Kimmel Cancer Center
        • Kontakt:
        • Hauptermittler:
          • Robyn D. Gartrell
    • Massachusetts
      • Boston, Massachusetts, Vereinigte Staaten, 02215
        • Rekrutierung
        • Dana-Farber Cancer Institute
        • Hauptermittler:
          • Allison F. O'Neill
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 877-442-3324
    • Michigan
      • Grand Rapids, Michigan, Vereinigte Staaten, 49503
        • Rekrutierung
        • Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital
        • Kontakt:
        • Hauptermittler:
          • Kathleen Y. Butler
    • Minnesota
      • Rochester, Minnesota, Vereinigte Staaten, 55905
        • Rekrutierung
        • Mayo Clinic in Rochester
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 855-776-0015
        • Hauptermittler:
          • Peter Schoettler
    • Mississippi
      • Jackson, Mississippi, Vereinigte Staaten, 39216
        • Rekrutierung
        • University of Mississippi Medical Center
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 601-815-6700
        • Hauptermittler:
          • Amanda Strobel
    • Missouri
      • Kansas City, Missouri, Vereinigte Staaten, 64108
        • Rekrutierung
        • Children's Mercy Hospitals and Clinics
        • Hauptermittler:
          • Keith J. August
        • Kontakt:
      • St Louis, Missouri, Vereinigte Staaten, 63110
        • Rekrutierung
        • Washington University School of Medicine
        • Kontakt:
        • Hauptermittler:
          • Frederick S. Huang
    • Nebraska
      • Omaha, Nebraska, Vereinigte Staaten, 68114
        • Rekrutierung
        • Children's Hospital and Medical Center of Omaha
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 402-955-3949
        • Hauptermittler:
          • Jill C. Beck
      • Omaha, Nebraska, Vereinigte Staaten, 68198
        • Rekrutierung
        • University of Nebraska Medical Center
        • Kontakt:
        • Hauptermittler:
          • Jill C. Beck
    • New Jersey
      • Hackensack, New Jersey, Vereinigte Staaten, 07601
        • Rekrutierung
        • Hackensack University Medical Center
        • Hauptermittler:
          • Katharine Offer
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 551-996-2897
      • Neptune City, New Jersey, Vereinigte Staaten, 07753
        • Rekrutierung
        • Jersey Shore Medical Center
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 732-776-4240
        • Hauptermittler:
          • Katharine Offer
      • New Brunswick, New Jersey, Vereinigte Staaten, 08903
        • Rekrutierung
        • Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital
        • Hauptermittler:
          • Scott Moerdler
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 732-235-8675
      • Newark, New Jersey, Vereinigte Staaten, 07112
        • Rekrutierung
        • Newark Beth Israel Medical Center
        • Kontakt:
        • Hauptermittler:
          • Teena Bhatla
    • New York
      • Albany, New York, Vereinigte Staaten, 12208
        • Rekrutierung
        • Albany Medical Center
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 518-262-5513
        • Hauptermittler:
          • Lauren R. Weintraub
      • The Bronx, New York, Vereinigte Staaten, 10467
        • Rekrutierung
        • Montefiore Medical Center - Moses Campus
        • Kontakt:
        • Hauptermittler:
          • Alice Lee
    • North Carolina
      • Charlotte, North Carolina, Vereinigte Staaten, 28203
        • Rekrutierung
        • Carolinas Medical Center/Levine Cancer Institute
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 800-804-9376
        • Hauptermittler:
          • Joel A. Kaplan
      • Durham, North Carolina, Vereinigte Staaten, 27710
        • Rekrutierung
        • Duke University Medical Center
        • Hauptermittler:
          • Jessica M. Sun
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 888-275-3853
      • Greenville, North Carolina, Vereinigte Staaten, 27834
        • Rekrutierung
        • East Carolina University
        • Kontakt:
        • Hauptermittler:
          • Andrea R. Whitfield
      • Winston-Salem, North Carolina, Vereinigte Staaten, 27157
        • Rekrutierung
        • Wake Forest University Health Sciences
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 336-713-6771
        • Hauptermittler:
          • Sarah Supples
    • North Dakota
      • Fargo, North Dakota, Vereinigte Staaten, 58122
    • Ohio
      • Cincinnati, Ohio, Vereinigte Staaten, 45229
        • Rekrutierung
        • Cincinnati Children's Hospital Medical Center
        • Kontakt:
        • Hauptermittler:
          • Brian K. Turpin
      • Cleveland, Ohio, Vereinigte Staaten, 44106
        • Rekrutierung
        • Rainbow Babies and Childrens Hospital
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 216-844-5437
        • Hauptermittler:
          • Duncan S. Stearns
      • Columbus, Ohio, Vereinigte Staaten, 43205
      • Dayton, Ohio, Vereinigte Staaten, 45404
        • Rekrutierung
        • Dayton Children's Hospital
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 800-228-4055
        • Hauptermittler:
          • Jordan M. Wright
    • Oklahoma
      • Oklahoma City, Oklahoma, Vereinigte Staaten, 73104
        • Rekrutierung
        • University of Oklahoma Health Sciences Center
        • Kontakt:
        • Hauptermittler:
          • Rene Y. McNall-Knapp
    • Pennsylvania
      • Allentown, Pennsylvania, Vereinigte Staaten, 18103
        • Rekrutierung
        • Lehigh Valley Hospital-Cedar Crest
        • Kontakt:
        • Hauptermittler:
          • Jacob A. Troutman
      • Hershey, Pennsylvania, Vereinigte Staaten, 17033
        • Rekrutierung
        • Penn State Children's Hospital
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 717-531-6012
        • Hauptermittler:
          • Lisa M. McGregor
      • Philadelphia, Pennsylvania, Vereinigte Staaten, 19104
        • Rekrutierung
        • Children's Hospital of Philadelphia
        • Kontakt:
        • Hauptermittler:
          • Theodore W. Laetsch
      • Pittsburgh, Pennsylvania, Vereinigte Staaten, 15224
        • Rekrutierung
        • Children's Hospital of Pittsburgh of UPMC
        • Kontakt:
        • Hauptermittler:
          • Brittani K. Seynnaeve
    • South Carolina
      • Columbia, South Carolina, Vereinigte Staaten, 29203
        • Rekrutierung
        • Prisma Health Richland Hospital
        • Hauptermittler:
          • Stuart L. Cramer
        • Kontakt:
      • Greenville, South Carolina, Vereinigte Staaten, 29605
        • Rekrutierung
        • BI-LO Charities Children's Cancer Center
        • Hauptermittler:
          • Aniket Saha
        • Kontakt:
    • South Dakota
      • Sioux Falls, South Dakota, Vereinigte Staaten, 57117-5134
    • Tennessee
      • Memphis, Tennessee, Vereinigte Staaten, 38105
        • Rekrutierung
        • Saint Jude Children's Research Hospital
        • Kontakt:
        • Hauptermittler:
          • Catherine G. Lam
      • Nashville, Tennessee, Vereinigte Staaten, 37232
        • Rekrutierung
        • Vanderbilt University/Ingram Cancer Center
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 800-811-8480
        • Hauptermittler:
          • Scott C. Borinstein
      • Nashville, Tennessee, Vereinigte Staaten, 37203
        • Rekrutierung
        • The Children's Hospital at TriStar Centennial
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 615-342-1919
        • Hauptermittler:
          • Clinton M. Carroll
    • Texas
      • Austin, Texas, Vereinigte Staaten, 78723
      • Dallas, Texas, Vereinigte Staaten, 75390
        • Rekrutierung
        • UT Southwestern/Simmons Cancer Center-Dallas
        • Kontakt:
        • Hauptermittler:
          • Avanthi T. Shah
      • Fort Worth, Texas, Vereinigte Staaten, 76104
      • Houston, Texas, Vereinigte Staaten, 77030
        • Rekrutierung
        • Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 713-798-1354
          • E-Mail: burton@bcm.edu
        • Hauptermittler:
          • Mehmet F. Okcu
      • Houston, Texas, Vereinigte Staaten, 77030
        • Rekrutierung
        • UT MD Anderson Cancer Center
        • Kontakt:
        • Hauptermittler:
          • Najat C. Daw
      • San Antonio, Texas, Vereinigte Staaten, 78207
        • Rekrutierung
        • Children's Hospital of San Antonio
        • Kontakt:
        • Hauptermittler:
          • Julie Voeller
    • Virginia
      • Charlottesville, Virginia, Vereinigte Staaten, 22908
      • Norfolk, Virginia, Vereinigte Staaten, 23507
        • Rekrutierung
        • Children's Hospital of The King's Daughters
        • Kontakt:
        • Hauptermittler:
          • Melissa S. Mark
      • Richmond, Virginia, Vereinigte Staaten, 23298
        • Rekrutierung
        • VCU Massey Comprehensive Cancer Center
        • Hauptermittler:
          • Madhu S. Gowda
        • Kontakt:
    • Washington
      • Seattle, Washington, Vereinigte Staaten, 98105
        • Rekrutierung
        • Seattle Children's Hospital
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 866-987-2000
        • Hauptermittler:
          • Sarah E. Leary
      • Tacoma, Washington, Vereinigte Staaten, 98405
        • Rekrutierung
        • Mary Bridge Children's Hospital and Health Center
        • Kontakt:
        • Hauptermittler:
          • Robert G. Irwin
    • Wisconsin
      • Milwaukee, Wisconsin, Vereinigte Staaten, 53226
        • Rekrutierung
        • Children's Hospital of Wisconsin
        • Hauptermittler:
          • Angela Steineck
        • Kontakt:

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

Nicht älter als 21 Jahre (Kind, Erwachsene)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  • Patients must be ≤ 21 years of age at the time of study enrollment

  • Newly diagnosed American Joint Committee on Cancer (AJCC) stage II-IV nasopharyngeal carcinoma (NPC)

    • Patients must have had histologic verification of the malignancy at original diagnosis
    • Although submission of tumor tissue for the molecular characterization initiative is not required for eligibility, it is strongly recommended
  • Patients must have had histologic verification of the malignancy at original diagnosis

  • Although submission of tumor tissue for the molecular characterization initiative is not required for eligibility, it is strongly recommended

  • Patients must have a Lansky (for patients ≤ 16 years of age) or Karnofsky (for patients > 16 years of age) performance status score of ≥ 60%

  • Peripheral absolute neutrophil count (ANC) ≥ 1000/uL (within 7 days prior to start of protocol therapy)

  • Platelet count ≥ 100,000/uL (transfusion independent) (within 7 days prior to start of protocol therapy)

  • Creatinine clearance or radioisotope glomerular filtration rate (GFR) ≥ 60 mL/min/1.73 m^2 or (within 7 days prior to start of protocol therapy)

  • A serum creatinine based on age/sex (within 7 days prior to start of protocol therapy) Age: Maximum serum creatinine (mg/dL)

    1 month to < 6 months: 0.4 mg/dL (male); 0.4 mg/dL (female) 6 months to < 1 year: 0.5 mg/dL (male); 0.5 mg/dL (female)

    1 to < 2 years: 0.6 mg/dL (male); 0.6 mg/dL (female) 2 to < 6 years: 0.8 mg/dL (male); 0.8 mg/dL (female) 6 to < 10 years 1 mg/dL (male); 1 mg/dL (female) 10 to <13 years: 1.2 mg/dL (male); 1.2 mg/dL (female) 13 to < 16 years: 1.5 mg/dL (male); 1.4 mg/dL (female)

    ≥ 16 years: 1.7 mg/dL (male); 1.4 mg/dL (female)

  • Total bilirubin ≤ 1.5 x upper limit of normal (ULN) for age, and (within 7 days prior to start of protocol therapy)

  • Serum glutamic-pyruvic transaminase (SGPT) (alanine aminotransferase [ALT]) ≤ 135 U/L* (within 7 days prior to start of protocol therapy)

    • Note: For the purpose of this study, the ULN for SGPT (ALT) has been set to the value of 45 U/L
  • Shortening fraction of ≥ 27% by echocardiogram, or

  • Ejection fraction of ≥ 50% by radionuclide angiogram

  • No evidence of dyspnea at rest, no exercise intolerance, and a pulse oximetry > 94% if there is clinical indication for determination

  • Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months and T-cell count above the lower limit of normal are eligible for this trial

  • For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated. Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load

Exclusion Criteria:

  • Patients who received prior radiotherapy to the head or neck

  • Patients who received prior chemotherapy or radiation for the treatment of any cancer in the last 3 years. These patients must also be in remission

  • Patients with a diagnosis of immunodeficiency

  • Patients with an active autoimmune disease that has required systemic treatment in the past 2 years (i.e., with use of disease-modifying agents, corticosteroids, or immunosuppressive agents). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.

    • Note: Patients with well-controlled asthma and no need for systemic steroids for the treatment of asthma in the last 12 months will not be excluded
  • Patients with a condition requiring systemic treatment with either corticosteroids (> 0.25 mg/kg (10 mg) daily prednisone equivalent) within 14 days or other immunosuppressive medications within 30 days of enrollment. Inhaled or topical steroids, and adrenal replacement steroid doses > 0.25 mg/kg (10 mg) daily prednisone equivalent, are permitted in the absence of active autoimmune disease

  • Patients with a history of (non-infectious) pneumonitis that required steroids or current pneumonitis

  • Patients with detectable viral load of human immunodeficiency virus (HIV), hepatitis B or hepatitis C, or active tuberculosis

  • Patients who have undergone solid organ or allogeneic hematopoietic transplant at any time

  • Due to risks of fetal and teratogenic adverse events as seen in animal studies, a negative pregnancy test must be obtained in females of childbearing potential, defined as females who are post-menarchal. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required

  • Females of childbearing potential that are sexually active must agree to either practice 2 medically accepted highly-effective methods of contraception at the same time or abstain from heterosexual intercourse from the time of signing the informed consent through 5 months after the last dose of nivolumab, 6 months after the last dose of gemcitabine, and 14 months after the last dose of cisplatin, whichever is longer

  • Males of childbearing potential that are sexually active must agree to either practice a medically accepted highly-effective methods of contraception or abstain from heterosexual intercourse from the time of signing the informed consent through 3 months after the last dose of gemcitabine, and 11 months after the last dose of cisplatin, whichever is longer

  • Lactating females are not eligible unless they have agreed not to breastfeed their infants starting with the first dose of study therapy through 5 months after the last dose of nivolumab

  • All patients and/or their parents or legal guardians must sign a written informed consent

  • All institutional, Food and Drug Administration (FDA), and National Cancer Institute (NCI) requirements for human studies must be met

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: N / A
  • Interventionsmodell: Einzelgruppenzuweisung
  • Maskierung: Keine (Offenes Etikett)

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: Treatment (nivolumab, gemcitabine, cisplatin, radiation)

See Detailed Description

Ancillary studies

Andere Namen:
  • Bewertung der Lebensqualität

Given IV

Andere Namen:
  • CDDP
  • Cis-Diamindichloridplatin
  • Cismaplat
  • Cisplatin
  • Neoplatin
  • Platinol
  • Abiplatin
  • Blastolem
  • Briplatin
  • Cis-Diammin-Dichlorplatin
  • Cis-Diamindichlorplatin (II)
  • Cis-Diamindichlorplatin
  • Cis-Dichloramin Platin (II)
  • Cis-Platindiamindichlorid
  • Cis-Platin
  • Cis-Platin II
  • Cis-Platin-II-Diamindichlorid
  • Cisplatyl
  • Citoplatino
  • Citosin
  • Cysplatyna
  • DDP
  • Lederplatin
  • Metaplatin
  • Peyrones Chlorid
  • Peyrones Salz
  • Platz
  • Kunststoff
  • Platamin
  • Platiblastin
  • Platiblastin-S
  • Platinex
  • Platinol- AQ
  • Platinol-AQ
  • Platinol-AQ VHA Plus
  • Platinoxan
  • Platin
  • Platindiaminodichlorid
  • Platiran
  • Plastin
  • Platosin

Undergo CT

Andere Namen:
  • CT
  • KATZE
  • Computertomographie
  • Computergestützte axiale Tomographie
  • CT-Scan
  • Tomographie
  • Computerisierte Axialtomographie (Verfahren)
  • Computertomographie (CT)-Scan
  • Diagnosekatze Scan
  • Diagnose -Katzen -Scan -Service -Typ

Undergo MRI

Andere Namen:
  • MRT
  • Magnetresonanz
  • Magnetresonanztomographie-Scan
  • Medizinische Bildgebung, Magnetresonanz / Kernspinresonanz
  • HERR
  • MR-Bildgebung
  • MRT-Untersuchung
  • NMR-Bildgebung
  • NMRI
  • Kernspinresonanztomographie
  • Magnetresonanztomographie (MRT)
  • sMRT
  • Magnetresonanztomographie (Verfahren)
  • MRTs
  • Strukturelle MRT

Ancillary studies

Undergo ECHO

Andere Namen:
  • Echokardiographie
  • EG

Undergo MUGA

Andere Namen:
  • Blutpool-Scan
  • Gleichgewichts-Radionuklid-Angiographie
  • Gated Blood Pool Imaging
  • MUGA
  • Radionuklid-Ventrikulographie
  • RNVG
  • SYMA-Scannen
  • Synchronisiertes Multigated Acquisition Scanning
  • MUGA-Scan
  • Multi-Gated Acquisition Scan
  • Radionuklid-Ventrikulogramm-Scan
  • Gated Heart Pool-Scan
  • RNV-Scan

Undergo PET

Andere Namen:
  • Medizinische Bildgebung, Positronen-Emissions-Tomographie
  • HAUSTIER
  • PET-Scan
  • Positronen-Emissions-Tomographie-Scan
  • Positronen-Emissions-Tomographie
  • Pt
  • Positronen-Emissions-Tomographie (Verfahren)

Given IV

Andere Namen:
  • BMS-936558
  • MDX-1106
  • NIVO
  • ONO-4538
  • Opdivo
  • CMAB819
  • Nivolumab-Biosimilar CMAB819
  • MDX1106
  • BMS 936558
  • ABP 206
  • Nivolumab Biosimilar ABP 206
  • BCD-263
  • Nivolumab-Biosimilar BCD-263
  • BMS936558
  • ONO 4538
  • ONO4538

Given IV

Andere Namen:
  • dFdCyd
  • dFdC
  • Difluordesoxycytidin

Undergo tissue biopsy

Andere Namen:
  • Bx
  • BIOPSY_TYPE
  • Biopsie

Undergo chest x-ray

Andere Namen:
  • Brust Röntgen

Ancillary studies

Receive radiation therapy

Andere Namen:
  • Strahlentherapie bei Krebs
  • ENERGY_TYPE
  • Bestrahlen
  • Bestrahlt
  • Bestrahlung
  • Strahlung
  • Strahlentherapie, NOS
  • Strahlentherapie
  • RT
  • Therapie, Bestrahlung
  • Energietyp

Undergo blood and stool sample collection

Andere Namen:
  • Biologische Probensammlung
  • Bioprobe gesammelt
  • Probenentnahme
  • Beispielsammlung

Given IV

Andere Namen:
  • (18F)Fluciclovin
  • (18F)GE-148
  • 18F-Fluciclovin
  • [18F]FACBC
  • Anti-(18f)FABC
  • Anti-1-Amino-3-[18F]Fluorcyclobutan-1-Carbonsäure
  • Anti-[18F] FACBC
  • Axumin
  • Fluciclovin (18F)
  • FLUCILOVIN F-18
  • GE-148 (18F)
  • GE-148 F-18

Undergo dental x-ray

Andere Namen:
  • Konventionelles Röntgen
  • Diagnostische Radiologie
  • Medizinische Bildgebung, Röntgen
  • Röntgenbildgebung
  • Radiographie
  • RG
  • Statisches Röntgen
  • Röntgen
  • Normalfilm-Röntgenaufnahmen
  • Röntgenbildgebendes Verfahren (Verfahren)

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Incidence of grade 3 or higher immune-related adverse events (irAE) during induction chemoimmunotherapy (CIT)
Zeitfenster: Until the end of consolidation therapy

Will be assessed by Common Terminology Criteria for Adverse Events. IrAEs include diarrhea (noninfectious), colitis (noninfectious), pneumonitis (noninfectious), myocarditis, elevated alanine aminotransferase, elevated aspartate aminotransferase, pancreatitis, elevated blood bilirubin, hypophysitis and hyperthyroid considered possibly, probably, or definitely related to nivolumab.

Until the end of consolidation therapy

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Event-free survival (EFS)
Zeitfenster: From date of enrollment to the earliest occurrence of date of relapse, disease progression, second malignant neoplasm or death due to any cause, assessed at 2 years

EFS along with the 95% confidence intervals will be estimated using the Kaplan-Meier method. The EFS will be reported separately for patients with non-metastatic disease and those with metastatic disease (if there are enough patients with metastatic disease enrolled).

From date of enrollment to the earliest occurrence of date of relapse, disease progression, second malignant neoplasm or death due to any cause, assessed at 2 years
Objective response rate
Zeitfenster: At the end of induction CIT

Will be defined as the rate of responders among evaluable patients using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.

At the end of induction CIT
Feasibility success of the induction regimen
Zeitfenster: At the end of induction CIT

Will be defined as the completion of three cycles of induction without delay of greater than 30 days for radiation initiation due to toxicity in 80% of patients.

At the end of induction CIT
Cumulative incidence of local or distant relapse
Zeitfenster: Up to 5 years

Defined as a function of time since enrollment will be estimated by the method of Gray.

Up to 5 years

Andere Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
EFS
Zeitfenster: At 5 years

Will be assessed using Kaplan-Meier estimates.

At 5 years
Overall survival
Zeitfenster: From date of enrollment to death due to any cause or date of last follow-up, assessed at 5 years

Will be assessed using Kaplan-Meier estimates.

From date of enrollment to death due to any cause or date of last follow-up, assessed at 5 years
Proportion of patients who achieve complete response
Zeitfenster: At the end of induction and maintenance

Will be assessed by retrospective central review by the proportion of patients who achieve complete response by magnetic resonance imaging using RECIST 1.1 criteria and the proportion of patients who achieve complete metabolic response using Positron Emission Tomography Response Criteria In Solid Tumors criteria at the end of induction and the end of maintenance based on central review will be presented. A two-way table of response assessments according to the two modalities will be constructed and McNemar's test will be performed to evaluate the concordance.

At the end of induction and maintenance
Protocol deviation related to radiation therapy delivery
Zeitfenster: Up to 5 years

Will be assessed by retrospective central review. The effect of deviation, categorized as present or absent by the central reviewer, on the hazard of EFS will be estimated by Cox proportional hazard model. The hazard ratio will be reported along with 95% confidence interval.

Up to 5 years
EFS in patients receiving intensity modulated radiation therapy with those who receive proton therapy
Zeitfenster: Up to 5 years

Will be assessed using a log-rank test.

Up to 5 years
Incidence of grade 3 or higher adverse events
Zeitfenster: Up to 5 years

Will be assessed during protocol therapy. The incidence of these events will be reported for each toxicity term. Furthermore, the irAE and toxicity related to radiation will be summarized by toxicity term and will be presented separately for the on-protocol therapy period and long-term follow-up.

Up to 5 years
Swallowing dysfunction
Zeitfenster: At baseline, during induction prior to start of chemoradioimmunotherapy (CRIT), each cycle throughout CRIT, within 3 months after maintenance and yearly at follow up, up to 5 years

Will be assessed using modified Functional Oral Intake Scale (FOIS) and pediatric Eating Assessment Tool (EAT)-10. The EAT-10 consists of 10 items scored from 0 (no impairment) to 4 (severe impairment). Total scores range from 0 to 40; higher scores indicate greater self-perceived impairment. Modified FOIS is an ordinal scale is a rating scale with 7 points for adults and 5 points in pediatrics. It is used to describe the feeding status and patients with dysphagia. Level 1 indicates inability to take anything by mouth while the highest point indicates full oral feeding. Will summarize responses from the modified FOIS and pediatric EAT-10 descriptively for each of these time points. A two-sided Wilcoxon rank-sum test will be performed to test the null hypothesis of equal score between two groups (who receive 54Gy versus 59.4Gy) at the end of the CRIT. Will evaluate the potential impact of other factors, as appropriate, such as baseline scores or disease stages for this analysis.

At baseline, during induction prior to start of chemoradioimmunotherapy (CRIT), each cycle throughout CRIT, within 3 months after maintenance and yearly at follow up, up to 5 years
Quality of life
Zeitfenster: At baseline, during induction prior to start of CRIT, each cycle throughout CRIT, within 3 months after maintenance and yearly at follow up, up to 5 years

Will be assessed using Patient-Reported Outcomes Measurement Information System (PROMIS). PROMIS includes multiple measures such as physical function mobility, anxiety, depressive symptoms, fatigue, etc. PROMIS use a T-score metric in which 50 is the mean of a relevant reference population and 10 is the standard deviation of that population. Higher T-score indicates more of the concept being measured. The numerical T scores of each domain will be summarized descriptively at every time point.

At baseline, during induction prior to start of CRIT, each cycle throughout CRIT, within 3 months after maintenance and yearly at follow up, up to 5 years
Lymphocyte-to-monocyte ratio (LMR)
Zeitfenster: At baseline, pre-radiation/consolidation, and post-radiation pre-maintenance

Will be assessed the ratio calculated by dividing the absolute lymphocyte count by the absolute monocyte count from a complete blood count with differential analysis performed. Lymphocyte and monocyte counts will be collected at the following time points: baseline, pre-radiation/consolidation, and post-radiation pre-maintenance. Cox proportional hazards regression will be used to evaluate the association between baseline LMR and EFS. The hazard ratio will be reported with a 95% confidence interval. In addition, the LMR will be summarized descriptively by the evaluation time points.

At baseline, pre-radiation/consolidation, and post-radiation pre-maintenance

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Ermittler

  • Hauptermittler: Robyn D Gartrell, Children's Oncology Group

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

25. Juni 2024

Primärer Abschluss (Geschätzt)

31. März 2027

Studienabschluss (Geschätzt)

31. März 2027

Studienanmeldedaten

Zuerst eingereicht

29. September 2023

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

29. September 2023

Zuerst gepostet (Tatsächlich)

3. Oktober 2023

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

14. Oktober 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

13. Oktober 2026

Zuletzt verifiziert

1. August 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Andere Studien-ID-Nummern

  • NCI-2023-07208
  • U10CA180886 (US NIH Stipendium/Vertrag)
  • NCI-2023-07208 (Registrierungskennung: CTRP (Clinical Trial Reporting Program))
  • ARAR2221 (Andere Kennung: CTEP)
  • ARAR2221 (Andere Kennung: Children's Oncology Group)

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

JA

Beschreibung des IPD-Plans

NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Ja

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Produkt, das in den USA hergestellt und aus den USA exportiert wird

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Abonnieren